Biomarkers of tuberculosis: a research roadmap. (June 2013)

• Record Type: Journal Article
• Authors: Whitworth, Hilary S; Aranday-Cortes, Elihu; Lalvani, Ajit
• Is Part Of: Biomarkers in medicine. Volume 7:Number 3(2013)
• Page Start: 349
• Page End: 362
• Publication Date: 2013-06
• Subjects: biomarker -- diagnosis -- immune markers -- latent TB infection -- LTBI -- metabolomics -- prognosis -- proteomics -- TB -- transcriptomics -- treatment response -- tuberculosis; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm.13.53
• Languages: English
• ISSNs: 1752-0363

Abstract

Tuberculosis (TB) continues to represent a major public health problem worldwide. Prompt and accurate diagnosis and effective treatment are fundamental to reducing morbidity and mortality and curtailing spread of infection. Furthermore, tackling the large reservoir of latent infection is the cornerstone to TB control in many high income low TB incidence countries. However, our existing toolkit for prevention, diagnosis and treatment remains outdated and inadequate. Here, we discuss the key targets for biomarker research and discovery in TB and recent developments in the field. We focus on host biomarkers, in particular: correlates of vaccine efficacy and sterilizing immunity; biomarkers of latent TB infection, including diagnosis, risk of progression to active TB and response to treatment; and markers of active TB, including diagnosis, response to treatment and risk of relapse. Recent scientific and technological advances have contributed to significant recent progression in biomarker discovery. Although there are clear remaining paucities, continued efforts within scientific, translational and clinical studies are likely to yield a number of clinically useful biomarkers of TB in the foreseeable future.